CoChat

A Feed-Forward Mechanosignaling Loop Confers Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutant Melanoma

Open access
Girard, Christophe A., Lecacheur, Margaux, Ben Jouira, Rania, Berestjuk, Ilona, Diazzi, Serena, Prod'homme, Virginie, Mallavialle, Aude, Larbret, Frédéric, Gesson, Maéva, Schaub, Sébastien, Pisano, Sabrina, Audebert, Stéphane, Mari, Bernard, Gaggioli, Cédric, Leucci, Eleonora, Marine, Jean-Christophe, Deckert, Marcel, Tartare-Deckert, Sophie · 2020 · Cancer Research
Cited by 70

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Aberrant extracellular matrix (ECM) deposition and stiffening is a physical hallmark of several solid cancers and is associated with therapy failure. BRAF-mutant melanomas treated with BRAF and MEK inhibitors almost invariably develop resistance that is frequently associated with transcriptional reprogramming and a de-differentiated cell state. Melanoma cells secrete their own ECM proteins, an event that is promoted by oncogenic BRAF inhibition. Yet, the contribution of cancer cell–derived ECM and tumor mechanics to drug adaptation and therapy resistance remains poorly understood. Here, we show that melanoma cells can adapt to targeted therapies through a mechanosignaling loop involving the autocrine remodeling of a drug-protective ECM. Analyses revealed that therapy-resistant cells associated with a mesenchymal dedifferentiated state displayed elevated responsiveness to collagen stiffening and force-mediated ECM remodeling through activation of actin-dependent mechanosensors Yes-associated protein (YAP) and myocardin-related transcription factor (MRTF). Short-term inhibition of MAPK pathway also induced mechanosignaling associated with deposition and remodeling of an aligned fibrillar matrix. This provided a favored ECM reorganization that promoted tolerance to BRAF inhibition in a YAP- and MRTF-dependent manner. Matrix remodeling and tumor stiffening were also observed in vivo upon exposure of BRAF-mutant melanoma cell lines or patient-derived xenograft models to MAPK pathway inhibition. Importantly, pharmacologic targeting of YAP reversed treatment-induced excessive collagen deposition, leading to enhancement of BRAF inhibitor efficacy. We conclude that MAPK pathway targeting therapies mechanically reprogram melanoma cells to confer a drug-protective matrix environment. Preventing melanoma cell mechanical reprogramming might be a promising therapeutic strategy for patients on targeted therapies. Significance: These findings reveal a biomechanical adaptation of melanoma cells to oncogenic BRAF pathway inhibition, which fuels a YAP/MRTF-dependent feed-forward loop associated with tumor stiffening, mechanosensing, and therapy resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-19-2914

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 18 references

Cited by

See all 70

Metadata

Authors
Girard, C. A., Lecacheur, M., Ben Jouira, R., Berestjuk, I., Diazzi, S., Prod'homme, V., Mallavialle, A., Larbret, F., Gesson, M., Schaub, S., Pisano, S., Audebert, S., Mari, B., Gaggioli, C., Leucci, E., Marine, J.-C., Deckert, M., & Tartare-Deckert, S.
Venue
Cancer Research
Published
2020-05-15
Volume
80
Issue
10
Pages
1927-1941
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W3010736313
Cited by
70
References
18
FWCI
3.46
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Feed-Forward Mechanosignaling Loop Confers Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutant Melanoma. https://app.cochat.ai/papers/10.1158/0008-5472.can-19-2914
The paper
Girard, C. A., Lecacheur, M., Ben Jouira, R., Berestjuk, I., Diazzi, S., Prod'homme, V., Mallavialle, A., Larbret, F., Gesson, M., Schaub, S., Pisano, S., Audebert, S., Mari, B., Gaggioli, C., Leucci, E., Marine, J.-C., Deckert, M., & Tartare-Deckert, S. (2020). A Feed-Forward Mechanosignaling Loop Confers Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutant Melanoma. Cancer Research. https://doi.org/10.1158/0008-5472.can-19-2914

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.